BenzingaSeptember 21, 2026 at 9:41 AM NYLast Month
B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $400
B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $392 to $400.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
